NCT07378306 2026-04-21
FACT-TN
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07078604 2026-04-07
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT07471815 2026-03-13
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Phase 2 Active not recruiting
NCT07342283 2026-03-02
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer
Affiliated Hospital of Nantong University
Phase 2 Recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT05076682 2025-12-03
Renaissance
Fudan University
Phase 2 Recruiting
NCT07108309 2025-08-07
AREAL
Biocad
Phase 2 Recruiting
NCT07104266 2025-08-05
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Phase 2 Recruiting
NCT07101614 2025-08-03
A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).
Shengjing Hospital
Phase 2 Not yet recruiting
NCT05300958 2025-07-22
Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer
Sun Yat-sen University
Phase 2 Terminated
NCT06691594 2025-02-20
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT02539017 2016-08-10
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Withdrawn